Related by context. All words. (Click for frequent words.) 71 Completes Enrollment 70 Improves Survival 70 Phase III Clinical Trial 69 Present Preclinical Data 69 Prolongs Survival 69 Completes Patient Enrollment 69 Meets Primary Endpoint 68 Drug Candidate 68 Initiates Phase III 68 FDA Okays 68 Preclinical Data 68 Phase 2b Trial 68 Clinical Trial Results 68 Kinase Inhibitor 67 Receives Orphan Drug Designation 67 Patients Treated With 67 Treating Chronic 67 Initiates Clinical Trial 67 JAK2 Inhibitor 67 Clinical Trial Evaluating 67 Lung Cancer Drug 67 Demonstrates Potential 67 Proves Effective 67 Anti Tumor Activity 67 Study Evaluating 67 Investigational Agent 67 Diabetic Foot Ulcer 67 Presents Positive 66 Prostate Cancer Patients 66 Anti Tumor 66 Enlarged Prostate 66 Adjuvant Chemotherapy 66 Patients Undergoing 66 Shows Promise Against 66 Postmenopausal Osteoporosis 66 Phase III Trial 66 Initiates Phase II 66 Novel Antibiotic 66 FDA Accepts 66 Granted Orphan Drug 66 Patients Treated 66 Presents Preclinical Data 66 Single Dose 65 Submits NDA 65 Newly Diagnosed Multiple Myeloma 65 Elderly Patients 65 Initiates Clinical 65 Teva Provides Update 65 Prospective Randomized 65 Mouse Model 65 Well Tolerated 65 Phase 2b Clinical Trial 65 Combination Treatment 65 Phase IIb Trial 65 Orally Active 65 Antitumor Activity 65 Randomized Clinical Trial 65 Diabetic Neuropathy 65 Drug Fails 65 Files IND 65 Node Positive 65 Treatment Regimen 65 Demonstrates Significant 65 Rheumatoid Arthritis Patients 65 Investigational Compound 65 Therapeutic Potential 65 Novel Oral 65 Inhibits 65 Long Term Efficacy 65 Shows Promising 65 Treatment Reduces 65 Initiates Enrollment 65 Protease Inhibitor 65 Slow Progression 65 Initiate Phase III 64 Dose Ranging Study 64 Systemic Delivery 64 Treatment Resistant 64 Survival Benefit 64 Rheumatoid Arthritis Drug 64 Phase IIb Clinical Trial 64 Renal Cell Carcinoma 64 Anticancer Activity 64 Breast Cancer Cells 64 Improves Outcomes 64 Previously Treated 64 Improved Survival 64 Pooled Analysis 64 Unfractionated Heparin 64 Advanced Melanoma 64 Hsp# Inhibitor 64 Low Dose 64 Clinical Efficacy 64 Statin Therapy 64 Progressive Multifocal Leukoencephalopathy 64 Newly Diagnosed 64 Bone Metastases 64 Diabetic Patients 64 Successfully Completes Phase 64 Lung Cancer Patients 64 Hormone Refractory Prostate Cancer 64 Randomized Controlled Trials 64 Anticancer Drugs 64 Demonstrates Sustained 64 Resistant Hypertension 64 Severe Sepsis 64 HCV Protease Inhibitor 64 Anticancer Drug 64 Spectrum Pharmaceuticals Announces 64 Drug Shows Promise 64 Myeloma Patients 64 HDAC Inhibitor 63 Shows Efficacy 63 NDA Submission 63 Disease Progression 63 Overactive Bladder 63 Patients Receiving 63 Phase IIa Clinical Trial 63 Double Blind Placebo 63 Complicated Skin 63 Completes Dosing 63 Stomach Cancer 63 Randomized Phase II 63 Colorectal Cancer Patients 63 Heart Failure Patients 63 Small Molecule 63 Multiple Myeloma Patients 63 Randomized Study 63 Phase 2a Clinical Trial 63 Tyrosine Kinase Inhibitor 63 Chemotherapy Regimen 63 Preclinical Study 63 Oral Fingolimod 63 Relapsed Refractory 63 Postmenopausal Women 63 See CLINICAL PHARMACOLOGY 63 Phase 1b Clinical Trial 63 Breast Cancer Patients 63 Lung Cancers 63 Controlled Trial 63 Improve Survival 63 Sapacitabine 63 Adjunctive Therapy 63 II Clinical Trial 63 Pharmacokinetic Study 63 Demonstrates Positive 63 Autoimmune Diseases 63 Advanced Prostate Cancer 63 Secondary Hyperparathyroidism 63 Adenoma 63 Monotherapy 63 JAK Inhibitor 62 Neuroendocrine Tumors 62 Pulmonary Arterial Hypertension 62 Investigational Treatment 62 Clinical Outcome 62 Myocardial Ischemia 62 Increased Mortality 62 Venous Thromboembolism 62 Breast Cancer Treatment 62 Inhaled Liposomal Ciprofloxacin 62 RNAi Therapeutics 62 Tumor Targeting 62 Placebo Controlled Trial 62 Pivotal Phase III 62 Pivotal Trial 62 Breast Cancer Recurrence 62 Phase 2b Study 62 Plaque Psoriasis 62 Diabetic Nephropathy 62 Sirolimus Eluting Stent 62 Autoimmune Disease 62 Therapeutic Efficacy 62 Humanized Anti 62 Lupus Drug 62 Hemodialysis Patients 62 Controlled Study 62 Metastatic Melanoma 62 Pegylated 62 Study Demonstrates 62 Oral Formulation 62 Advanced Ovarian Cancer 62 Patient Enrollment 62 Phase III Trials 62 Adjuvant Treatment 62 Predict Response 62 Liver Tumors 62 Localized Prostate Cancer 62 Randomized Trials 62 Dose Escalation 62 Myelodysplastic Syndromes 62 Files Investigational 62 Adjuvant Therapy 62 Recombinant Human 62 Drug Eluting 62 Lung Cancer Trial 62 Metabolic Efficiency 62 PKC# 62 Randomized Double Blind 62 Chronic Sinusitis 62 Pivotal Phase 62 Cardiovascular Events 62 Hepatocellular Carcinoma 62 Prostate Cancer Treatment 62 Advanced Renal Cell 61 Chronic Hepatitis C 61 Oncolytic Reovirus 61 Increased Risk 61 Meta Analysis 61 Investigational Drug 61 Hematological Malignancies 61 Relapsing Multiple Sclerosis 61 Intracranial Aneurysms 61 Novel Treatments 61 HER2 Positive Breast Cancer 61 Initiates Phase 61 Knee Osteoarthritis 61 Tumor Cell 61 Brain Metastases 61 Treatment Naive 61 Prospective Multicenter 61 Gene Mutation 61 Metastatic Colorectal Cancer 61 Metastatic Pancreatic Cancer 61 Chronic Hepatitis B 61 Carotid Stenting 61 Chemotherapeutic Agents 61 Dose Escalation Study 61 Reports Preclinical Data 61 Gene Linked 61 HER2 Positive 61 Randomized Double blind 61 Kinase Inhibitors 61 Combination Clinical Trial 61 Inflammatory Disease 61 Bosutinib 61 Demonstrates Potent 61 Initiates Phase 2b 61 Plus Ribavirin 61 Regimens 61 Advanced Colorectal Cancer 61 Liver Metastases 61 Study Showed 61 Genes Identified 61 Statistically Significant 61 Breast Cancers 61 Randomized Controlled Trial 61 Novel Mechanism 61 Pharmacokinetics PK 61 Bladder Cancer 61 Anthracycline 61 PRN FDA Approves 61 Therapeutic Vaccine 61 Renal Cancer 61 Chronic Myeloid Leukemia 61 Tezampanel 61 Gets FDA Clearance 61 Cutaneous T 61 Randomized Phase 61 Gastric Cancer 61 Metastatic Prostate Cancer 61 Previously Untreated 61 Test Detects 61 Pivotal Study 61 RNAi Therapeutic 61 Vaccine Adjuvant 61 Paclitaxel Carboplatin 61 Randomized Phase III 60 Treatment Naïve 60 Phase 2a Trial 60 Autologous Stem Cell Transplantation 60 Predict Risk 60 Tumor Growth 60 Improve Outcomes 60 Myelofibrosis 60 Tumor Necrosis Factor 60 Hedgehog Pathway 60 Refractory Hodgkin Lymphoma 60 Demonstrated Significant 60 Gemcitabine 60 Treated Patients 60 Initiate Clinical Trial 60 Tyrosine Kinase Inhibitors 60 Antigen Specific 60 Anticoagulants 60 fosbretabulin 60 TNF Blockers 60 Is Well Tolerated 60 Peginterferon 60 Clinical Trial Data 60 Radical Prostatectomy 60 Aurora Kinase 60 Neoadjuvant 60 Unresectable 60 Combination REOLYSIN R 60 Hematological Cancers 60 Benign Prostatic Hyperplasia 60 MEK Inhibitor 60 Endometrial Cancer 60 Romidepsin 60 Combination Therapy 60 Initiate Phase 60 Efficacious 60 Bevacizumab 60 Renal Tumors 60 Receives Fast Track 60 Fluorouracil 60 Breast Tumors 60 Platelet Inhibition 60 Soft Tissue Sarcoma 60 Prostate Biopsy 60 Fixed Dose 60 Aliskiren 60 Hepatitis C Virus 60 Lupus Nephritis 60 Epidermal Growth Factor Receptor 60 Antiangiogenic 59 Commences Phase 59 Diabetic Neuropathic Pain 59 Deforolimus 59 Stem Cell Transplants 59 Nilotinib 59 Begins Dosing 59 Genes Predict 59 Chronic Lymphocytic Leukemia 59 erlotinib Tarceva ® 59 ISTODAX ® 59 Atypical Hemolytic Uremic Syndrome 59 Presents Preclinical 59 Allergic Rhinitis 59 Relapsed Multiple Myeloma 59 Phase III Pivotal 59 Brentuximab Vedotin SGN 59 Systematic Review 59 Subgroup Analysis 59 Invasive Breast Cancer 59 dasatinib Sprycel ® 59 Malignant Glioma 59 Multicenter Phase 59 Blood Pressure Lowering 59 Androgen Deprivation Therapy 59 Antiviral Activity 59 Dose Ranging 59 Dendritic Cells 59 Aggressive Prostate Cancer 59 Sipuleucel T 59 Randomized Double Blind Placebo 59 Taxane 59 Acute Ischemic Stroke 59 Acute Coronary Syndromes 59 Gastrointestinal Disorders 59 Drug Resistant 59 Receives Orphan Drug 59 Ovarian Cancer Patients 59 Tanespimycin 59 Subtypes 59 Telaprevir VX 59 Orphan Diseases 59 Erectile Dysfunction Drug 59 Endothelial Cells 59 Treatment Naive Patients 59 Cardiovascular Outcomes 59 Pivotal Clinical Trial 59 Ranolazine 59 ST Segment Elevation 59 Antifungals 59 Receives Positive Opinion 59 essential thrombocythemia ET 59 novel emulsion formulation 59 IL# PE#QQR 59 Chronic Heart Failure 59 Progenitor Cells 59 Neoadjuvant Chemotherapy 59 Cardiotoxicity 59 Phase III Clinical Trials 58 Enzyme Replacement Therapy 58 familial amyloidotic polyneuropathy FAP 58 IgG1 monoclonal antibody 58 Preclinical Models 58 Clostridium difficile Infection 58 5 Fluorouracil 58 Hyperlipidemia 58 docetaxel Taxotere ® 58 Insulin Resistance 58 Hypercholesterolemia 58 Contrast Agents 58 Naive Patients 58 INSPIRE Trial Phase III 58 Radiofrequency Ablation 58 Squamous Cell Carcinoma 58 Radioimmunotherapy 58 Myelodysplastic Syndrome 58 Glufosfamide 58 Pegylated Liposomal Doxorubicin 58 Viral Suppression 58 Therapy Evaluation 58 Severe Asthma 58 Anticancer Compound 58 Newly Diagnosed Patients 58 B Cell Malignancies 58 Bortezomib 58 Factor Receptor 58 Malignant Melanoma 58 TO AVOID PREGNANCY WHILE 58 Advanced Solid Tumors 58 Renal Cell Cancer 58 Inflammatory Diseases 58 Solid Tumors 58 Pafuramidine 58 Castration Resistant Prostate Cancer 58 Trial Evaluating 58 Azacitidine 58 Immunotherapeutic 58 Safinamide 58 Hepatocellular 58 Randomized Controlled 58 Acute Myocardial Infarction 58 Metastatic Renal Cell Carcinoma 58 Psoriasis Patients 58 LENALIDOMIDE 58 Estrogen Receptor 58 Percutaneous Coronary Intervention 58 Rectal Cancer 58 Elotuzumab 57 Disease Modifying 57 Oral Mucositis 57 5 FU leucovorin 57 Therapeutic Competitors Companies 57 Virus Infection 57 Disease Modification 57 Pazopanib 57 Emerging Therapies 57 Myelodysplastic Syndrome MDS 57 Carboplatin Paclitaxel 57 Romiplostim 57 Vaccine Candidate 57 Dasatinib 57 Xcytrin R 57 Carcinoma 57 Ischemic 57 Cell Lung Cancer 57 Announces Poster Presentations 57 Chronic Myelogenous Leukemia 57 Pertuzumab 57 Prostate Cancers 57 Dupuytren Contracture 57 Autoimmune Disorders 57 Serious Infections 57 Anti TNF 57 Chemoradiation 57 Infected Patients 57 Prognostic Significance 57 5 fluorouracil leucovorin 57 Relapsing Remitting Multiple Sclerosis 57 investigational oral inhibitor 57 CYT# potent vascular disrupting 57 Novel Small Molecule 57 Pemetrexed 57 Anti CD# Antibody 57 Molecular Diagnostic Test 57 Advanced Pancreatic Cancer 57 Tumor Response 57 Paraplatin ® 57 evaluating picoplatin 57 Sangamo BioSciences Announces 57 Multicenter Randomized 56 Decitabine 56 Treatment Experienced 56 Ozarelix 56 Mayo Clinic Study Finds 56 Newly Diagnosed Breast Cancer 56 Adjuvant 56 Abiraterone Acetate 56 Personalized Immunotherapy 56 Achieves Primary Endpoint 56 Diffuse Large B 56 Tolerability 56 Capecitabine 56 Gemzar ® 56 Bivalirudin 56 Breast Density 56 Pegylated Interferon 56 Cancer Patients Treated 56 Analytical Tool 56 Chronic Lymphocytic Leukemia CLL 56 NICE Recommends 56 Follicular Lymphoma 56 Embolization 56 Degarelix 56 Philadelphia Chromosome Positive 56 sorafenib Nexavar 56 Esophageal Cancer 56 ARRY # 56 Skin Cancers 56 Leukemias 56 intravesical infusion therapy 56 Peginterferon Alfa 2b 56 BRIM2 56 Carcinomas 56 Copegus R 56 Denufosol 56 Cell Lymphoma 56 dasatinib Sprycel 56 ASCO GI 56 Topline Results 56 Therapeutic Targets 56 Lenalidomide 56 Uterine Fibroid Embolization 56 Allogeneic 56 brand ciclesonide HFA 56 Targeted Therapy 56 Interferon Alfa 56 Acute Myeloid Leukemia 56 Pralatrexate 56 pralatrexate injection folate analogue 56 Aflibercept 56 Medullary Thyroid Cancer 56 Voreloxin 56 sunitinib Sutent 55 Golimumab 55 Antiviral Therapy 55 Trastuzumab DM1 55 Observational Study 55 Nitazoxanide 55 R roscovitine 55 Relapsed 55 Vitro Activity 55 interferon gamma 1b 55 Interferon Beta 55 imatinib Gleevec ® 55 Vidaza ® 55 recurrent metastatic ovarian cancer 55 Nymox NX 55 Relapsed Refractory Multiple Myeloma 55 Metastases 55 candidates Azedra TM 55 Irinotecan 55 Erlotinib 55 Malignancies 55 Temsirolimus 55 thalidomide Thalomid 55 Fludara ® 55 oncolytic virus therapies 55 Meet Primary Endpoint 55 Enzastaurin 55 Carfilzomib 55 Trastuzumab 55 Cypher Sirolimus 55 Adalimumab 55 Patient Outcomes 55 Metastatic Disease 55 R roscovitine CDK cyclin 55 Monoclonal Antibody 55 pan HDAC inhibitor 55 Cancer Therapies 55 cutaneous T 55 ritonavir boosted 55 Fabry Disease 55 Vaccine Protects Against 55 Tesetaxel 55 Targeted Therapies 55 ST Elevation Myocardial 55 SUTENT ® 55 Cethromycin 55 Bavituximab 54 B Cell Lymphoma 54 Xeloda capecitabine 54 Liver Cancer 54 Pancreatic Adenocarcinoma 54 Hedgehog Pathway Inhibitor 54 AVASTIN 54 adalimumab Humira 54 Albuferon TM 54 investigational humanized monoclonal antibody 54 Stereotactic Body Radiation Therapy 54 dependent kinase inhibitor 54 Rheumatoid Arthritis 54 vinca alkaloid 54 Daclizumab 54 sorafenib tablets 54 LHRH receptor positive 54 MKC# MKC# PP 54 Phase 2a Study 54 Alemtuzumab 54 Omacetaxine 54 Sorafenib 54 Cancer Vaccines 54 oral nucleoside analogue 54 FOLOTYN ® 54 Lacosamide 54 investigational immunotherapy 54 metastatic malignant 54 AAG geldanamycin analog 54 KRN# 54 Thromboembolism 54 Acute Exacerbations 54 Metastatic Breast Cancer 54 Peginterferon alfa 2b 54 Ofatumumab 54 Therapeutic Antibodies 54 PEGylated Fab fragment 54 Hormone Receptor Positive 54 Apaziquone 54 Monoclonal Antibodies 54 cell lymphoma CTCL 54 Thyroid Cancer 54 PROSTASCINT R 54 Synta Announces 54 Line Metastatic Colorectal 54 Glioblastoma Multiforme 54 Elagolix 54 gefitinib Iressa 54 Mantle Cell Lymphoma 53 sunitinib Sutent ® 53 Hodgkin lymphoma HL 53 Epratuzumab 53 Cancer Incidence Mortality 53 Atopic Dermatitis 53 Cetuximab Erbitux 53 novel VDA molecule 53 Clofarabine 53 Unstable Angina 53 ThermoDox R 53 ZACTIMA TM ZD# 53 Ambrisentan 53 paclitaxel Taxol R 53 Completes Patient Enrolment 53 papillary renal cell carcinoma 53 Vidaza azacitidine 53 Camptosar ® 53 hypereosinophilic syndrome 53 receptor tyrosine kinase inhibitor 53 Bronchiectasis 53 Dapagliflozin 53 Docetaxel 53 Adenomas 53 PEGylated interferon beta 1a 53 trastuzumab Herceptin R 53 Natalizumab 53 Potent Anti 53 metastatic colorectal 53 Diabetic Macular Edema 53 metastatic castration resistant 53 Permanent Prostate Brachytherapy 53 Universal Flu Vaccine 53 FOLFOX6 53 SPRYCEL ® 53 Maribavir 53 Pirfenidone 53 Stage IIIb 53 histone deacetylase HDAC inhibitor 53 erythematosus 53 Carboplatin 53 Picoplatin Efficacy After 53 atypical Hemolytic Uremic Syndrome 52 oral prodrug 52 Cloretazine 52 Relapsed Refractory Aggressive 52 ALN HPN 52 topoisomerase II inhibitor 52 Motesanib 52 unresectable stage 52 Bosentan 52 Outpatient Setting 52 FOLFOX6 chemotherapy regimen 52 sarcoma melanoma 52 Phase Ib II 52 DIRECT Trial 52 Friedreich Ataxia FRDA 52 prostate cancer HRPC 52 bevacizumab Avastin ® 52 bevacizumab Avastin 52 Glioma 52 YONDELIS 52 metastatic hormone refractory 52 Phase III Pivotal Trial 52 including eniluracil ADH 52 ZOLINZA 52 Palifosfamide 52 metastatic ocular 52 Gastrointestinal Stromal Tumors 52 stage IIIB 52 Imatinib 52 standard chemotherapy regimen 52 Panzem R NCD 52 corticotropin injection 52 Kamada AAT 52 Mitoxantrone 52 HoFH 52 PNP inhibitor 51 Phase #b/#a clinical 51 PROVENGE ® 51 ZACTIMA 51 advanced metastatic renal 51 Prednisone Against Refractory 51 targeted radiotherapeutic 51 Gefitinib 51 metastatic neuroendocrine tumors 51 Annamycin 51 mertansine 51 EGFR TKI 51 SABCS 51 refractory chronic lymphocytic 51 YONDELIS R 51 multi kinase inhibitor 51 myelofibrosis polycythemia vera 51 Complete Remission 51 MKC# MT 51 Kit CD# positive 51 AVOREN 51 AA Amyloidosis 51 nab paclitaxel 51 Lymphomas 51 Civacir 51 Hepatocellular Carcinoma HCC 51 antibody MAb 51 lymphoid malignancies 51 Perifosine 51 mGluR5 negative 51 metastatic castrate resistant 51 systemic anaplastic large 51 oral proteasome inhibitor 51 Aplidin R 51 BR.# 50 MCSP respectively 50 apoptosis inducer 50 TTR amyloidosis 50 Metastatic 50 Vandetanib 50 registrational Phase 50 metastatic renal cell carcinoma 50 paclitaxel Taxol 50 HCV SPRINT 50 Cerebril TM 50 leukemia AML 50 autologous cellular immunotherapy 50 evaluating tivozanib 50 agonistic human 50 PDX pralatrexate 50 Cancer Immunotherapy 50 biliary tract cancer 50 SCH # 50 Renal Cell Carcinoma RCC 50 severe oral mucositis 50 Panzem NCD 50 ORENCIA ® 50 Stage IIB 50 Ulcerative Colitis 50 monoclonal antibody conjugated 50 recurrent NSCLC 50 targeting CD# 50 fallopian tube cancers 50 Xelox 50 gastrointestinal stromal tumors GIST 50 Seliciclib 50 Cloretazine ® 50 ixabepilone 50 castrate resistant prostate cancer 50 PANVAC VF 50 ENDEAVOR IV 50 Papillary 50 Idiopathic Pulmonary Fibrosis 50 Taxotere ® 50 angiogenesis inhibitor 50 MyVax R 50 depsipeptide 50 HGS ETR1 mapatumumab 49 panitumumab Vectibix 49 advanced hepatocellular carcinoma 49 VEGFR2 inhibitor 49 metastatic colorectal carcinoma 49 Adenocarcinoma 49 recurrent glioblastoma multiforme 49 basal cell carcinoma BCC 49 non resectable 49 FOLFIRI 49 Entereg R 49 multicenter Phase II 49 MAGE A3 ASCI 49 Vorinostat 49 colorectal liver metastases 49 refractory cutaneous T 49 metastatic GIST 49 ovarian esophageal 49 Advaxis Phase 49 Acute Myeloid Leukemia AML 49 STRIDE PD 49 relapsed refractory multiple myeloma 49 Evoltra ® 49 Amrubicin 49 Squamous 49 MGd 49 prostate cancer mCRPC 49 mapatumumab 49 Skin Structure Infections ABSSSI 49 Myocardial Infarction Study 49 unresectable Stage III 49 IMC #B 48 sunitinib malate 48 Nexavar sorafenib 48 estramustine 48 HuMax EGFr 48 CTAP# Capsules 48 InNexus Biotechnology Announces 48 PSMA ADC 48 recurrent glioma 48 PRT# 48 Herceptin trastuzumab 48 metastatic gastric 48 neratinib 48 PROVENGE sipuleucel T 48 prostate cancer CRPC 48 Velcade bortezomib 48 Cloretazine R 48 vascular disrupting agent 48 Doxil ® 48 CA4P 48 lung pancreatic 48 Hepatitis C Virus HCV 48 Gleevec resistant 48 Nexavar ® 48 metastatic pancreatic 48 #I TM# 48 Quinamed 48 ALN TTR 48 gemcitabine Gemzar 48 CIMZIA ™ 48 Bezielle 48 ErbB2 positive 48 metastatic renal 48 liposomal doxorubicin 47 phase IIb trial 47 Pancreatic Cancer 47 cetuximab Erbitux 47 invasive bladder 47 huC# DM4 47 trastuzumab DM1 T DM1 47 Chronic lymphocytic leukemia 47 SAR# [004] 47 fallopian tube carcinoma 47 Solazed TM 47 stage IIIb IV 47 pertuzumab 47 antibody MT# 47 BRAF inhibitor 47 Phase Ib clinical trials 47 Folfox 47 Cell Non Hodgkin 47 CYC# 47 tubulin inhibitor 47 Pegasys ® 47 leukemia CLL 47 Exherin TM 47 resistant hormone refractory 47 trastuzumab Herceptin ® 47 Vitaxin 47 invasive candidiasis 47 temsirolimus 47 Overactive Bladder OAB 47 completely resected 47 KRAS mutation 47 lymphoma CTCL 46 Chronic Myelogenous Leukemia CML 46 Dacogen injection 46 unresectable locally advanced 46 bladder ovarian 46 liposomal amphotericin B 46 tumors GIST 46 Genasense ® 46 recurrent GBM 46 relapsed multiple myeloma 46 recurrent metastatic 46 gastrointestinal stromal tumors 46 predictive biomarkers 46 cancer mCRC 46 IMC A# 46 Trofex 46 trabectedin 46 severe hypersensitivity reactions 46 HER2 positive metastatic breast 46 TORISEL 46 Multiple Myeloma 46 PD LID 46 alvespimycin 45 androgen independent 45 ganetespib 45 Zolinza 45 refractory multiple myeloma 45 nonmetastatic 45 L BLP# 45 BRIM3 45 Clinical Trials Review 45 neoadjuvant treatment 45 keloid scarring 45 relapsed ovarian cancer 45 eosinophilic asthma 45 xenograft models 45 malignant pleural mesothelioma 45 CR# vcMMAE 45 hormone deprivation 45 AEG# 45 SCCHN 45 ongoing Phase 1b 45 medically inoperable 45 cisplatin chemotherapy 44 cediranib 44 bone metastasis 44 RGB # 44 neoadjuvant therapy 44 vandetanib 44 velafermin 44 PXD# 44 phase IIb clinical 44 Neuvenge 44 LUX Lung 44 forodesine 44 HRPC 44 Tamibarotene 44 Tarceva erlotinib 44 EGFr 44 IMA# 43 hepatocellular carcinoma HCC 43 lung ovarian 43 panobinostat 43 olaparib 43 assessing T DM1 43 cell lymphoma ALCL 43 pancreatic adenocarcinoma 43 Crohn disease CD 43 NSCLC tumors 43 epithelial tumors 43 stage IIIB IV 43 neoadjuvant 43 axitinib 43 phase IIb study 43 HGS ETR1 43 carcinoid tumors 43 neuroendocrine cancers 43 nonsmall cell lung cancer 42 resistant ovarian cancer 42 registrational trial 42 OncoVEX GM CSF 42 advanced unresectable 42 enzastaurin 42 invasive lobular carcinoma 42 non squamous 42 metastatic RCC 42 amrubicin 42 Zybrestat 42 heavily pretreated 42 squamous non 41 aflibercept 41 cutaneous T cell 41 commonly mutated genes 41 randomized Phase III 41 seminoma 41 neuroendocrine tumors 41 GISTs 41 Midsized Businesses 41 unresectable 41 anti EGFR antibody 41 Phase #/#a trial 41 pancreatic NET 41 Cholangiocarcinoma 41 breast pancreatic 41 ALCL 41 lung carcinomas 40 lintuzumab 40 IV melanoma 40 cell carcinoma 40 OPAXIO 40 non squamous NSCLC 40 MAGE A3 40 platinum refractory 40 recurrent ovarian cancer 40 metastatic liver 40 hepatocellular cancer 40 taxane therapy 40 Allovectin 7 R 40 follicular non 39 renal cell carcinoma 39 bladder cancers 39 NSCLC 39 medullary thyroid cancer 39 B CLL 39 TTF Therapy 39 AP# [003] 38 squamous cell lung cancer 38 HNSCC 37 advanced NSCLC 37 HER2 positive 37 squamous 35 ASA# 35 metastatic renal cell 35 metastatic colorectal cancer 35 metastatic breast 34 KRAS wild 34 cell lung cancer 28 lung cancers